FindMyKOL
Clinical trialNCT00243191CompletedPhase 2Interventional

Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

NCT00243191 is a phase 2 interventional trial sponsored by Sarcoma Alliance for Research through Collaboration. As of 21 Nov 2026, it is completed. It studies Imatinib in Dermatofibrosarcoma Protuberans. The registry lists an enrollment of 18 participants at 4 sites in 1 country. The registry lists a start date of 31 May 2006 and a primary completion date of 30 Sept 2009. One of its registered investigators has a FindMyKOL profile.

SponsorSarcoma Alliance for Research through Collaboration →Enrollment18Dermatofibrosarcoma Protuberans
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00243191
FieldValue
Registry IDNCT00243191
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorSarcoma Alliance for Research through Collaboration
Enrollment18
Registered sites4
Countries1
ConditionsDermatofibrosarcoma Protuberans
DrugsImatinib
Start31 May 2006
Primary completion30 Sept 2009
Study completion30 Sept 2009
Last update posted29 Mar 2012

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to examine the effect of imatinib on dermatofibrosarcoma protuberan tumors.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Florida, United States1 site
  • H. Lee Moffitt Cancer Center

    Tampa

Michigan, United States1 site
  • University of Michigan Comprehensive Cancer Center

    Ann Arbor

Pennsylvania, United States1 site
  • Pennsylvania Onc/hem Assoc.

    Philadelphia

Texas, United States1 site
  • Md Anderson Cancer Center

    Houston

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichigan: 1 siteMI1New YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvania: 1 sitePA1New JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 siteTX1Florida: 1 siteFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00243191

Each answer restates registry values shown on this page.

What is NCT00243191?

NCT00243191 is a phase 2 interventional trial sponsored by Sarcoma Alliance for Research through Collaboration. It studies Imatinib in Dermatofibrosarcoma Protuberans.

Who leads NCT00243191?

The registry names Scott Schuetze, MD, PhD (principal investigator, University of Michigan) as the overall official.

Where does NCT00243191 run?

The registry lists 4 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00243191 study?

The registered drug and biological interventions are Imatinib.

When did NCT00243191 end?

The registry lists a primary completion date of 30 Sept 2009 and a study completion date of 30 Sept 2009. The sponsor last updated the record on 29 Mar 2012.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.